Format

Send to

Choose Destination
Radiother Oncol. 2019 Oct;139:83-86. doi: 10.1016/j.radonc.2019.07.018. Epub 2019 Aug 17.

Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Author information

1
Radiation Oncology, Geneva University Hospital, Switzerland; Faculty of Medicine, Geneva University, Switzerland. Electronic address: Thomas.Zilli@hcuge.ch.
2
Radiation Oncology, Humanitas Research Hospital and Cancer Center, Milan, Italy.
3
Radiation Oncology, Geneva University Hospital, Switzerland.
4
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don-Calabria, Negrar, Italy.
5
Radiation Oncology, University Hospital Zürich, Switzerland.
6
Radiation Oncology, Kantonsspital Graubünden, Chur, Switzerland.
7
Methodology and Biostatistics Unit, Centre Georges François Leclerc, Dijon, France.
8
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don-Calabria, Negrar, Italy; University of Brescia, Faculty of Medicine, Brescia, Italy.
9
Radiation Oncology, Humanitas University, Milan, Italy; Radiation Oncology, Humanitas Research Hospital and Cancer Center, Milan, Italy.
10
Radiation Oncology, Geneva University Hospital, Switzerland; Faculty of Medicine, Geneva University, Switzerland.

Abstract

The ONE SHOT trial is the first phase I/II prospective, multicenter, single-arm study assessing the efficacy and safety of a single-dose SBRT for men with localized prostate cancer. Aim of this paper is to present the phase I results of a 19 Gy single fraction urethra-sparing SBRT with real-time electromagnetic tracking.

KEYWORDS:

Monotherapy; Phase I/II trial; Prostate cancer; SBRT; Toxicity

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center